HC Wainwright & Co. Maintains Buy on Revolution Medicines, Raises Price Target to $195

Benzinga Newsdesk www.benzinga.com Positive 73.4%

Neg 0% Neu 0% Pos 73.4%

HC Wainwright & Co. analyst Robert Burns maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $169 to $195.